Research progress on the neuroprotective effect of stem cells in age-related macular degeneration_Chinese Journal of Ocular Fundus Diseases

Authors：

Fang Jiansheng ¹ ,  Du Yuxiang ²

1. College of Clinical Medicine, Jining Medical University, Jining 272067, China;
2. Institute of Precision Medicine, Jining Medical University, Jining 272067, China;

Corresponding author：

Du Yuxiang, Email: dyx622@163.com

Keywords：

Age-related macular degeneration; Stem cell; Therapy; Neuroprotection; Review

DOI：

10.3760/cma.j.cn511434-20240925-00358

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Age-related macular degeneration (AMD) is an age-related neurodegenerative eye disease characterized by degeneration and progressive death of retinal pigment epithelium (RPE) and photoreceptor cells. In recent years, as a new treatment for AMD, stem cell therapy has attracted wide attention in the field of AMD, and has become a current research hotspot. Although stem cell therapy carries risks such as increased incidence of cancer and immune rejection, it significantly promotes damaged photoreceptor cells and retinal cells by differentiating into RPE cells and other retinal cell types, as well as secreting neurotrophic factors and extracellular vesicles. In particular, the development of embryonic stem cell-derived RPE cells, its cryopreservation technology and the advancement of plasmid, adeno-associated virus, Sendai virus and other delivery technologies have laid a solid foundation for stem cell therapy of AMD. As a new method to prevent retinal damage and photoreceptor degeneration, stem cell neuroprotective therapy has shown great potential, and with the continuous maturity and improvement of these technologies, stem cell therapy is expected to provide new ideas for the prevention and treatment of AMD in the future.

Citation： Fang Jiansheng, Du Yuxiang. Research progress on the neuroprotective effect of stem cells in age-related macular degeneration. Chinese Journal of Ocular Fundus Diseases, 2025, 41(2): 156-162. doi: 10.3760/cma.j.cn511434-20240925-00358 Copy

1.
2.	Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis[J/OL]. Lancet Glob Health, 2014, 2(2): e106-e116[2014-01-03]. https://pubmed.ncbi.nlm.nih.gov/25104651/. DOI: 10.1016/s2214-109x(13)70145-1.
3.
4.
5.
6.
7.
8.
9.	Rohowetz LJ, Koulen P. Stem cell-derived retinal pigment epithelium cell therapy: past and future directions[J/OL]. Front Cell Dev Biol, 2023, 11: 1098406[2023-04-30]. https://pubmed.ncbi.nlm.nih.gov/37065847/. DOI: 10.3389/fcell.2023.1098406.
10.	Singh MS, Park SS, Albini TA, et al. Retinal stem cell transplantation: balancing safety and potential[J/OL]. Prog Retin Eye Res, 2020, 75: 100779[2019-09-05]. https://pubmed.ncbi.nlm.nih.gov/31494256/. DOI: 10.1016/j.preteyeres.2019.100779.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.	Yu B, Shao H, Su C, et al. Exosomes derived from MSC ameliorate retinal laser injury partially by inhibition of MCP-1[J/OL]. Sci Rep, 2016, 6: 34562[2016-09-30]. https://pubmed.ncbi.nlm.nih.gov/27686625/. DOI: 10.1038/srep34562.
31.	Dezfuly AR, Safaee A, Amirpour N, et al. Therapeutic effects of human adipose mesenchymal stem cells and their paracrine agents on sodium iodate induced retinal degeneration in rats[J/OL]. Life Sci, 2022, 300: 120570[2022-07-01]. https://pubmed.ncbi.nlm.nih.gov/35469914/. DOI: 10.1016/j.lfs.2022.120570.
32.
33.
34.
35.
36.
37.
38.	Zhang T, Qian C, Song M, et al. Application prospect of induced pluripotent stem cells in organoids and cell therapy[J/OL]. Int J Mol Sci, 2024, 25(5): 2680[2024-02-26]. https://pubmed.ncbi.nlm.nih.gov/38473926/. DOI: 10.3390/ijms25052680.
39.
40.	Rodriguez-Polo I, Mißbach S, Petkov S, et al. A piggyBac-based platform for genome editing and clonal rhesus macaque iPSC line derivation[J/OL]. Sci Rep, 2021, 11(1): 15439[2021-07-29]. https://pubmed.ncbi.nlm.nih.gov/34326359/. DOI: 10.1038/s41598-021-94419-7.
41.
42.	Yang Y, Liu B, Dong J, et al. Proteins reprogramming: present and future[J/OL]. Scientific World J, 2012, 2012: 453185[2012-11-22]. https://pubmed.ncbi.nlm.nih.gov/23226982/. DOI: 10.1100/2012/453185.
43.	Lutfi Ismaeel G, Makki AlHassani OJ, S Alazragi R, et al. Genetically engineered neural stem cells (NSC) therapy for neurological diseases; state-of-the-art[J/OL]. Biotechnol Prog, 2023, 39(5): e3363[2023-05-23]. https://pubmed.ncbi.nlm.nih.gov/37221947/.DOI: 10.1002/btpr.3363.
44.
45.	Rhee KD, Nusinowitz S, Chao K, et al. CNTF-mediated protection of photoreceptors requires initial activation of the cytokine receptor gp130 in Müller glial cells[J/OL]. Proc Natl Acad Sci USA, 2013, 110(47): E4520-4529[2013-11-19]. https://pubmed.ncbi.nlm.nih.gov/24191003/. DOI: 10.1073/pnas.1303604110.
46.	Miralles de Imperial-Ollero JA, Gallego-Ortega A, Ortín-Martínez A, et al. Animal models of LED-induced phototoxicity. Short- and long-term in vivo and ex vivo retinal alterations[J/OL]. Life (Basel), 2021, 11(11): 1137[2021-10-26]. https://pubmed.ncbi.nlm.nih.gov/34833013/. DOI: 10.3390/life11111137.
47.	Mattern L, Otten K, Miskey C, et al. Molecular and functional characterization of BDNF-overexpressing human retinal pigment epithelial cells established by sleeping beauty transposon-mediated gene transfer[J/OL]. Int J Mol Sci, 2022, 23(21): 12982[2022-10-26]. https://pubmed.ncbi.nlm.nih.gov/36361771/. DOI: 10.3390/ijms232112982.
48.	Amadoro G, Latina V, Balzamino BO, et al. Nerve growth factor-based therapy in Alzheimer's disease and age-related macular degeneration[J/OL]. Front Neurosci, 2021, 15: 735928[2021-09-09]. https://pubmed.ncbi.nlm.nih.gov/34566573/. DOI: 10.3389/fnins.2021.735928.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.

1.
2. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis[J/OL]. Lancet Glob Health, 2014, 2(2): e106-e116[2014-01-03]. https://pubmed.ncbi.nlm.nih.gov/25104651/. DOI: 10.1016/s2214-109x(13)70145-1.
3.
4.
5.
6.
7.
8.
9. Rohowetz LJ, Koulen P. Stem cell-derived retinal pigment epithelium cell therapy: past and future directions[J/OL]. Front Cell Dev Biol, 2023, 11: 1098406[2023-04-30]. https://pubmed.ncbi.nlm.nih.gov/37065847/. DOI: 10.3389/fcell.2023.1098406.
10. Singh MS, Park SS, Albini TA, et al. Retinal stem cell transplantation: balancing safety and potential[J/OL]. Prog Retin Eye Res, 2020, 75: 100779[2019-09-05]. https://pubmed.ncbi.nlm.nih.gov/31494256/. DOI: 10.1016/j.preteyeres.2019.100779.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30. Yu B, Shao H, Su C, et al. Exosomes derived from MSC ameliorate retinal laser injury partially by inhibition of MCP-1[J/OL]. Sci Rep, 2016, 6: 34562[2016-09-30]. https://pubmed.ncbi.nlm.nih.gov/27686625/. DOI: 10.1038/srep34562.
31. Dezfuly AR, Safaee A, Amirpour N, et al. Therapeutic effects of human adipose mesenchymal stem cells and their paracrine agents on sodium iodate induced retinal degeneration in rats[J/OL]. Life Sci, 2022, 300: 120570[2022-07-01]. https://pubmed.ncbi.nlm.nih.gov/35469914/. DOI: 10.1016/j.lfs.2022.120570.
32.
33.
34.
35.
36.
37.
38. Zhang T, Qian C, Song M, et al. Application prospect of induced pluripotent stem cells in organoids and cell therapy[J/OL]. Int J Mol Sci, 2024, 25(5): 2680[2024-02-26]. https://pubmed.ncbi.nlm.nih.gov/38473926/. DOI: 10.3390/ijms25052680.
39.
40. Rodriguez-Polo I, Mißbach S, Petkov S, et al. A piggyBac-based platform for genome editing and clonal rhesus macaque iPSC line derivation[J/OL]. Sci Rep, 2021, 11(1): 15439[2021-07-29]. https://pubmed.ncbi.nlm.nih.gov/34326359/. DOI: 10.1038/s41598-021-94419-7.
41.
42. Yang Y, Liu B, Dong J, et al. Proteins reprogramming: present and future[J/OL]. Scientific World J, 2012, 2012: 453185[2012-11-22]. https://pubmed.ncbi.nlm.nih.gov/23226982/. DOI: 10.1100/2012/453185.
43. Lutfi Ismaeel G, Makki AlHassani OJ, S Alazragi R, et al. Genetically engineered neural stem cells (NSC) therapy for neurological diseases; state-of-the-art[J/OL]. Biotechnol Prog, 2023, 39(5): e3363[2023-05-23]. https://pubmed.ncbi.nlm.nih.gov/37221947/.DOI: 10.1002/btpr.3363.
44.
45. Rhee KD, Nusinowitz S, Chao K, et al. CNTF-mediated protection of photoreceptors requires initial activation of the cytokine receptor gp130 in Müller glial cells[J/OL]. Proc Natl Acad Sci USA, 2013, 110(47): E4520-4529[2013-11-19]. https://pubmed.ncbi.nlm.nih.gov/24191003/. DOI: 10.1073/pnas.1303604110.
46. Miralles de Imperial-Ollero JA, Gallego-Ortega A, Ortín-Martínez A, et al. Animal models of LED-induced phototoxicity. Short- and long-term in vivo and ex vivo retinal alterations[J/OL]. Life (Basel), 2021, 11(11): 1137[2021-10-26]. https://pubmed.ncbi.nlm.nih.gov/34833013/. DOI: 10.3390/life11111137.
47. Mattern L, Otten K, Miskey C, et al. Molecular and functional characterization of BDNF-overexpressing human retinal pigment epithelial cells established by sleeping beauty transposon-mediated gene transfer[J/OL]. Int J Mol Sci, 2022, 23(21): 12982[2022-10-26]. https://pubmed.ncbi.nlm.nih.gov/36361771/. DOI: 10.3390/ijms232112982.
48. Amadoro G, Latina V, Balzamino BO, et al. Nerve growth factor-based therapy in Alzheimer's disease and age-related macular degeneration[J/OL]. Front Neurosci, 2021, 15: 735928[2021-09-09]. https://pubmed.ncbi.nlm.nih.gov/34566573/. DOI: 10.3389/fnins.2021.735928.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.

Chinese Journal of Ocular Fundus Diseases

Research progress on the neuroprotective effect of stem cells in age-related macular degeneration

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content